Cell Line

Rat tail collagen

Cell Sep

LLC-WRC 256, Lilly Laboratories Culture-Walker Rat Culture 256

Please note this product may be subject to fees, we invite you to contact your local office. PRAME TCR CD8⁺ NFAT-Luciferase Reporter Jurkat Cell Line was generated from T Cell Receptor (TCR) Knockout NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #78556) by overexpression of human CD8 (NM_001768.6) and a PRAME (Preferentially Expressed Antigen in Melanoma)-directed TCR using lentiviral transduction (CD8a Lentivirus #78648 and PRAME-Specific TCR Lentivirus #78959). This PRAME TCR specifically recognizes an antigen PRAME peptide, amino acids peptide 425-433 (SLLQHLIGL).

Please note this product may be subject to fees, we invite you to contact your local office. The Vγ4Vδ1 TCR NFAT-Luciferase Reporter Jurkat Cell Line was generated from the T Cell Receptor (TCR) Knockout NFAT Luciferase Reporter Jurkat Cell Line (#78556) by overexpression of human Vγ4Vδ1 TCR using lentiviral transduction (with Vγ4Vδ1 TCR Lentivirus #78986). This cell line was functionally validated with a TCR Vδ1 agonist antibody.

Please note this product may be subject to fees, we invite you to contact your local office. The MDA-MB-436 cell line is derived from a human breast adenocarcinoma. This cell line is characterized by its triple-negative breast cancer (TNBC) phenotype, lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Such characteristics make it an invaluable model for studying TNBC, a particularly aggressive and difficult-to-treat subtype of breast cancer. The cells exhibit an epithelial morphology and are known for their robust proliferative capacity in vitro. Genetically, MDA-MB-436 cells harbor mutations in key cancer-related genes, including BRCA1 and TP53. The BRCA1 mutation is of particular interest, as it mirrors the genetic alterations found in a subset of hereditary breast cancers. This makes MDA-MB-436 a crucial tool for investigating the mechanisms underlying BRCA1-associated tumorigenesis and for testing potential t

Please note this product may be subject to fees, we invite you to contact your local office. The Transduction Control (Tet-On) iPS Cell Pool is an iPS (induced pluripotent stem) cell pool that was generated via lentiviral transduction with Expression Negative Control Lentivirus (Inducible Tet-On) (#82290). This cell pool can be used as control for Cas9 Inducible (Tet-On) iPS Cell Pool (BPS Bioscience #78845).

Please note this product may be subject to fees, we invite you to contact your local office. This cell line was generated by transducing the TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line (BPS Bioscience #78556) with lentiviruses (CD4 Lentivirus, Bioscience #78987) to overexpress human CD4 (NM_000616.5). To achieve knockout of TCR (T Cell Receptor), the TRAC (T-Cell Receptor Alpha Constant) and TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from Jurkat cells that stably expressed firefly luciferase under the control of NFAT response elements. TCRα/β knockout in the TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line was confirmed by both genomic sequencing and flow cytometry. Expression of CD4 in CD4⁺ TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line was confirmed by flow cytometry. The cell line does not respond to anti-CD3 agonist antibodies, as opposed to the parental NFAT-Lucife

Please note this product may be subject to fees, we invite you to contact your local office. IL-23 Responsive STAT3 Luciferase Reporter HEK293 Cell Line is an engineered HEK293 cell line expressing firefly luciferase under the control of STAT3 response element, and human IL-23 receptor complex (IL12Rβ1 NM_005535.3 and IL23R NM_144701.3). With this cell line, IL-23 activity can be monitored by measuring luciferase activity. The functionality of the IL-23 Responsive STAT3 Luciferase Reporter HEK293 Cell Line was validated in dose-response assays using a recombinant human interleukin 23 (human IL-23; p19 + p40), inhibition assays using the anti-IL-23 antibodies Ustekinumab and Guselkumab, as well as a Janus Kinase inhibitor, Ruxolitinib.